KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kyverna Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.83+0.16 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Kyverna Therapeutics has not reported a dividend
No dividend per share appears in Kyverna Therapeutics's annual filings since fiscal 2022.